Immune escape of AML cells after transplantation

Matthew Christopher; John F. DiPersio; Timothy J. Ley

doi:10.1056/NEJMc1900424

Immune escape of AML cells after transplantation

Matthew Christopher, John F. DiPersio, Timothy J. Ley

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	1289-1290
Number of pages	2
Journal	New England Journal of Medicine
Volume	380
Issue number	13
DOIs	https://doi.org/10.1056/NEJMc1900424
State	Published - Mar 28 2019

Access to Document

10.1056/NEJMc1900424

Cite this

@article{9fd0689d76b244518b9baee5fd509e2c,

title = "Immune escape of AML cells after transplantation",

author = "Matthew Christopher and DiPersio, {John F.} and Ley, {Timothy J.}",

note = "Funding Information: Dr. Goodman reports receiving speaker{\textquoteright}s fees from Seattle Genetics and consulting fees from Jazz Pharmaceuticals; and Dr. Kurzrock, receiving research funding from Genentech, In-cyte, Merck, Serono, Pfizer, Sequenom, Foundation Medicine, and Guardant Health, consulting fees from Loxo Oncology, XBiotech, and Actuate Therapeutics, and speaker{\textquoteright}s fees from Roche and holding an ownership interest in CureMatch. No other potential conflict of interest relevant to this letter was reported.",

year = "2019",

month = mar,

day = "28",

doi = "10.1056/NEJMc1900424",

language = "English",

volume = "380",

pages = "1289--1290",

journal = "New England Journal of Medicine",

issn = "0028-4793",

number = "13",

}

TY - JOUR

T1 - Immune escape of AML cells after transplantation

AU - Christopher, Matthew

AU - DiPersio, John F.

AU - Ley, Timothy J.

N1 - Funding Information: Dr. Goodman reports receiving speaker’s fees from Seattle Genetics and consulting fees from Jazz Pharmaceuticals; and Dr. Kurzrock, receiving research funding from Genentech, In-cyte, Merck, Serono, Pfizer, Sequenom, Foundation Medicine, and Guardant Health, consulting fees from Loxo Oncology, XBiotech, and Actuate Therapeutics, and speaker’s fees from Roche and holding an ownership interest in CureMatch. No other potential conflict of interest relevant to this letter was reported.

PY - 2019/3/28

Y1 - 2019/3/28

UR - http://www.scopus.com/inward/record.url?scp=85063577781&partnerID=8YFLogxK

U2 - 10.1056/NEJMc1900424

DO - 10.1056/NEJMc1900424

M3 - Letter

C2 - 30917273

AN - SCOPUS:85063577781

SN - 0028-4793

VL - 380

SP - 1289

EP - 1290

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 13

ER -

Immune escape of AML cells after transplantation

Access to Document

Other files and links

Cite this